Portfolio

Contact:   John Kurek

BioParticle Technologies is focused on the development and commercialisation of its novel proprietary drug delivery platform called ARISE (Atomised Rapid Injection for Solvent Extraction).  ARISE is a second generation, super critical fluid solvent extraction technology that generates, from pharmaceutical mixtures, aerodynamic, nanosized particulates with improved surface area and particle size distribution.  This process provides an effective means for drug delivery for those drugs that are currently available either as an oral or as an intravenous formulation but for which direct pulmonary exposure would be of clinical benefit.  BioParticle Technologies is actively seeking partnership with a suitable pharmaceutical or delivery device manufacturer that would benefit from application of the ARISE technology.